High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients. / Sejdic, Adin; Frische, Anders; Jørgensen, Charlotte Sværke; Rasmussen, Lasse Dam; Trebbien, Ramona; Dungu, Arnold; Holler, Jon G.; Ostrowski, Sisse Rye; Eriksson, Robert; Søborg, Christian; Nielsen, Thyge L.; Fischer, Thea K.; Lindegaard, Birgitte; Franck, Kristina Træholt; Harboe, Zitta Barrella.

In: Virology Journal, Vol. 20, No. 1, 14, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Sejdic, A, Frische, A, Jørgensen, CS, Rasmussen, LD, Trebbien, R, Dungu, A, Holler, JG, Ostrowski, SR, Eriksson, R, Søborg, C, Nielsen, TL, Fischer, TK, Lindegaard, B, Franck, KT & Harboe, ZB 2023, 'High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients', Virology Journal, vol. 20, no. 1, 14. https://doi.org/10.1186/s12985-023-01974-8

APA

Sejdic, A., Frische, A., Jørgensen, C. S., Rasmussen, L. D., Trebbien, R., Dungu, A., Holler, J. G., Ostrowski, S. R., Eriksson, R., Søborg, C., Nielsen, T. L., Fischer, T. K., Lindegaard, B., Franck, K. T., & Harboe, Z. B. (2023). High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients. Virology Journal, 20(1), [14]. https://doi.org/10.1186/s12985-023-01974-8

Vancouver

Sejdic A, Frische A, Jørgensen CS, Rasmussen LD, Trebbien R, Dungu A et al. High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients. Virology Journal. 2023;20(1). 14. https://doi.org/10.1186/s12985-023-01974-8

Author

Sejdic, Adin ; Frische, Anders ; Jørgensen, Charlotte Sværke ; Rasmussen, Lasse Dam ; Trebbien, Ramona ; Dungu, Arnold ; Holler, Jon G. ; Ostrowski, Sisse Rye ; Eriksson, Robert ; Søborg, Christian ; Nielsen, Thyge L. ; Fischer, Thea K. ; Lindegaard, Birgitte ; Franck, Kristina Træholt ; Harboe, Zitta Barrella. / High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients. In: Virology Journal. 2023 ; Vol. 20, No. 1.

Bibtex

@article{a054084b14104b15ba42fbdf61352f8b,

title = "High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients",

abstract = "Background: Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity, infectious viral shedding and NAb titers as well as the association between NAb titers and disease severity in hospitalized COVID-19 patients in Denmark 2020–2021. Materials and methods: Prospective single-center observational cohort study of 47 hospitalized COVID-19 patients. Oropharyngeal swabs were collected at eight time points during the initial 30 days of inclusion. Serum samples were collected after a median time of 7 (IQR 5 – 10), 37 (IQR 35 – 38), 97 (IQR 95 – 100), and 187 (IQR 185 – 190) days after symptom onset. NAb titers were determined by an in-house live virus microneutralization assay. Viral culturing was performed in Vero E6 cells. Results: Patients with high disease severity had higher mean log2 NAb titers at day 37 (1.58, 95% CI [0.34 –2.81]), 97 (2.07, 95% CI [0.53–3.62]) and 187 (2.49, 95% CI [0.20– 4.78]) after symptom onset, compared to patients with low disease severity. Peak viral load (0.072, 95% CI [− 0.627 – 0.728]), expressed as log10 SARS-CoV-2 copies/ml, was not associated with disease severity. Virus cultivation attempts were unsuccessful in almost all (60/61) oropharyngeal samples collected shortly after hospital admission. Conclusions: We document an association between high disease severity and high mean NAb titers at days 37, 97 and 187 after symptom onset. However, peak viral load during admission was not associated with disease severity. Trial registration. The study is registered at https://clinicaltrials.gov/ (NCT05274373).",

keywords = "COVID-19, Disease severity, Neutralizing antibodies, Viral culturing, Viral load",

author = "Adin Sejdic and Anders Frische and J{\o}rgensen, {Charlotte Sv{\ae}rke} and Rasmussen, {Lasse Dam} and Ramona Trebbien and Arnold Dungu and Holler, {Jon G.} and Ostrowski, {Sisse Rye} and Robert Eriksson and Christian S{\o}borg and Nielsen, {Thyge L.} and Fischer, {Thea K.} and Birgitte Lindegaard and Franck, {Kristina Tr{\ae}holt} and Harboe, {Zitta Barrella}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

doi = "10.1186/s12985-023-01974-8",

language = "English",

volume = "20",

journal = "Virology Journal",

issn = "1743-422X",

publisher = "BioMed Central",

number = "1",

}

RIS

TY - JOUR

T1 - High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients

AU - Sejdic, Adin

AU - Frische, Anders

AU - Jørgensen, Charlotte Sværke

AU - Rasmussen, Lasse Dam

AU - Trebbien, Ramona

AU - Dungu, Arnold

AU - Holler, Jon G.

AU - Ostrowski, Sisse Rye

AU - Eriksson, Robert

AU - Søborg, Christian

AU - Nielsen, Thyge L.

AU - Fischer, Thea K.

AU - Lindegaard, Birgitte

AU - Franck, Kristina Træholt

AU - Harboe, Zitta Barrella

PY - 2023

Y1 - 2023

N2 - Background: Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity, infectious viral shedding and NAb titers as well as the association between NAb titers and disease severity in hospitalized COVID-19 patients in Denmark 2020–2021. Materials and methods: Prospective single-center observational cohort study of 47 hospitalized COVID-19 patients. Oropharyngeal swabs were collected at eight time points during the initial 30 days of inclusion. Serum samples were collected after a median time of 7 (IQR 5 – 10), 37 (IQR 35 – 38), 97 (IQR 95 – 100), and 187 (IQR 185 – 190) days after symptom onset. NAb titers were determined by an in-house live virus microneutralization assay. Viral culturing was performed in Vero E6 cells. Results: Patients with high disease severity had higher mean log2 NAb titers at day 37 (1.58, 95% CI [0.34 –2.81]), 97 (2.07, 95% CI [0.53–3.62]) and 187 (2.49, 95% CI [0.20– 4.78]) after symptom onset, compared to patients with low disease severity. Peak viral load (0.072, 95% CI [− 0.627 – 0.728]), expressed as log10 SARS-CoV-2 copies/ml, was not associated with disease severity. Virus cultivation attempts were unsuccessful in almost all (60/61) oropharyngeal samples collected shortly after hospital admission. Conclusions: We document an association between high disease severity and high mean NAb titers at days 37, 97 and 187 after symptom onset. However, peak viral load during admission was not associated with disease severity. Trial registration. The study is registered at https://clinicaltrials.gov/ (NCT05274373).

AB - Background: Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity, infectious viral shedding and NAb titers as well as the association between NAb titers and disease severity in hospitalized COVID-19 patients in Denmark 2020–2021. Materials and methods: Prospective single-center observational cohort study of 47 hospitalized COVID-19 patients. Oropharyngeal swabs were collected at eight time points during the initial 30 days of inclusion. Serum samples were collected after a median time of 7 (IQR 5 – 10), 37 (IQR 35 – 38), 97 (IQR 95 – 100), and 187 (IQR 185 – 190) days after symptom onset. NAb titers were determined by an in-house live virus microneutralization assay. Viral culturing was performed in Vero E6 cells. Results: Patients with high disease severity had higher mean log2 NAb titers at day 37 (1.58, 95% CI [0.34 –2.81]), 97 (2.07, 95% CI [0.53–3.62]) and 187 (2.49, 95% CI [0.20– 4.78]) after symptom onset, compared to patients with low disease severity. Peak viral load (0.072, 95% CI [− 0.627 – 0.728]), expressed as log10 SARS-CoV-2 copies/ml, was not associated with disease severity. Virus cultivation attempts were unsuccessful in almost all (60/61) oropharyngeal samples collected shortly after hospital admission. Conclusions: We document an association between high disease severity and high mean NAb titers at days 37, 97 and 187 after symptom onset. However, peak viral load during admission was not associated with disease severity. Trial registration. The study is registered at https://clinicaltrials.gov/ (NCT05274373).

KW - COVID-19

KW - Disease severity

KW - Neutralizing antibodies

KW - Viral culturing

KW - Viral load

U2 - 10.1186/s12985-023-01974-8

DO - 10.1186/s12985-023-01974-8

M3 - Journal article

C2 - 36698135

AN - SCOPUS:85146878971

VL - 20

JO - Virology Journal

JF - Virology Journal

SN - 1743-422X

IS - 1

M1 - 14

ER -

ID: 336447489